Terms: = Lung cancer AND ROS1, ROS, 6098, ENSG00000047936, P08922, MCF3, RP1-179P9_1
122604 results:
1. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
Ding W; Chen L; Xia J; Pei B; Song B; Li X
Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
[TBL] [Abstract] [Full Text] [Related]
2. Video-Assisted vs Robotic-Assisted lung Lobectomies for Operating Room Resource Utilization and Patient Outcomes.
Tupper HI; Lawson BL; Kipnis P; Patel AR; Ashiku SK; Roubinian NH; Myers LC; Liu VX; Velotta JB
JAMA Netw Open; 2024 May; 7(5):e248881. PubMed ID: 38700865
[TBL] [Abstract] [Full Text] [Related]
3. Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC.
Lu Y; Langerman SS; McCain E; Magee K; Maund SL; Srivastava MK; Samant M
JAMA Netw Open; 2024 May; 7(5):e249286. PubMed ID: 38700864
[TBL] [Abstract] [Full Text] [Related]
4. Knockdown of NADK promotes LUAD ferroptosis via NADPH/FSP1 axis.
Meng X; Peng F; Yu S; Chi X; Wang W; Shao S
J Cancer Res Clin Oncol; 2024 May; 150(5):228. PubMed ID: 38700533
[TBL] [Abstract] [Full Text] [Related]
5. Association between advanced lung cancer inflammation index and all-cause and cardiovascular mortality among stroke patients: NHANES, 1999-2018.
Chen X; Hong C; Guo Z; Huang H; Ye L
Front Public Health; 2024; 12():1370322. PubMed ID: 38699426
[TBL] [Abstract] [Full Text] [Related]
6. Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.
Lou J; Gong B; Li Y; Guo Y; Li L; Wang J; Liu W; You Z; Zhang H; Pan F; Liang B; Yang L; Zhou G
Front Immunol; 2024; 15():1332303. PubMed ID: 38698843
[TBL] [Abstract] [Full Text] [Related]
7. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
[TBL] [Abstract] [Full Text] [Related]
8. Radicality of mediastinal lymphadenectomy in minimally invasive pulmonary resection: a comparative analysis of uniportal and multiportal thoracoscopic approaches.
Tulinský L; Kepičová M; Ihnát P; Mitták M; Adamica D; Čierna L; Martínek L
Rozhl Chir; 2024; 103(2):48-56. PubMed ID: 38697813
[TBL] [Abstract] [Full Text] [Related]
9. Association of log odds of positive lymph nodes with survival in patients with small cell lung cancer: Results from the SEER database.
Gao T; Chang Y; Yue H
Clinics (Sao Paulo); 2024; 79():100369. PubMed ID: 38696974
[TBL] [Abstract] [Full Text] [Related]
10. lung cancer-specific symptoms and fear of cancer recurrence among recurrence-free non-small cell lung cancer survivors.
Lee G; Ahn A; Lee D; Kim TE; Kong S; Kang D; Kim HK; Shim YM; Cho J
Support Care Cancer; 2024 May; 32(5):322. PubMed ID: 38695959
[TBL] [Abstract] [Full Text] [Related]
11. Primary lung cancer in children and adolescents.
Chen Q; Cheng J; Wang L; Lv X; Hu J
J Cancer Res Clin Oncol; 2024 May; 150(5):225. PubMed ID: 38695944
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis.
Gong S; Li Q; Yu X; Yang S
Front Immunol; 2024; 15():1362537. PubMed ID: 38694505
[TBL] [Abstract] [Full Text] [Related]
13. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.
Takayama K; Kojima A; Honda C; Nakayama M; Kanemata S; Endo T; Muro K
Cancer Med; 2024 May; 13(9):e7170. PubMed ID: 38693813
[TBL] [Abstract] [Full Text] [Related]
14. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
[TBL] [Abstract] [Full Text] [Related]
15. Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors.
Fu XP; Ji CY; Tang WQ; Yu TT; Luo L
Clin Exp Med; 2024 May; 24(1):93. PubMed ID: 38693424
[TBL] [Abstract] [Full Text] [Related]
16. Value of turbo spin echo-based diffusion-weighted imaging in the differential diagnosis of benign and malignant solitary pulmonary lesions.
Lei Q; Liu L; Li J; Yu K; Yin Y; Wang J; Su S; Song Y; Jiang G
Sci Rep; 2024 Apr; 14(1):9965. PubMed ID: 38693152
[TBL] [Abstract] [Full Text] [Related]
17. Injectable hydrogel with doxorubicin-loaded ZIF-8 nanoparticles for tumor postoperative treatments and wound repair.
Zhang Q; Zhang Y; Chen H; Sun LN; Zhang B; Yue DS; Wang CL; Zhang ZF
Sci Rep; 2024 May; 14(1):9983. PubMed ID: 38693143
[TBL] [Abstract] [Full Text] [Related]
18. Applications of Artificial Intelligence in lung Pathology.
Hartman DJ
Surg Pathol Clin; 2024 Jun; 17(2):321-328. PubMed ID: 38692814
[TBL] [Abstract] [Full Text] [Related]
19. Microsatellite Instability, Mismatch Repair, and Tumor Mutation Burden in lung cancer.
Rosca OC; Vele OE
Surg Pathol Clin; 2024 Jun; 17(2):295-305. PubMed ID: 38692812
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Implications of Small Cell lung cancer Transcriptional Subtyping for CNS Metastases.
Tringale KR; Skakodub A; Egger J; Eichholz J; Yu Y; Gomez D; Rimner A; Li B; Yamada Y; Wilcox J; Moss N; Imber BS; Rekhtman N; Baine MK; Rudin CM; Pike LRG
JCO Precis Oncol; 2024 Apr; 8():e2300470. PubMed ID: 38691815
[TBL] [Abstract] [Full Text] [Related]
[Next]